López-Muñoz F, Sim K, Shen WW, Huelves L, Moreno R, Molina JD, Rubio G, Noriega C, Pérez-Nieto MA, Álamo C
Correspondence: Prof Francisco López-Muñoz, francisco.lopez.munoz@gmail.com
ABSTRACT
INTRODUCTION A bibliometric study was carried out to ascertain the volume and impact of scientific literature published on second-generation antipsychotic drugs (SGAs) in Singapore from 1997 to 2011.
METHODS A search of the EMBASE and MEDLINE databases was performed to identify articles originating from Singapore that included the descriptors ‘atypic* antipsychotic*’, ‘second-generation antipsychotic*’, ‘clozapine’, ‘risperidone’, ‘olanzapine’, ‘ziprasidone’, ‘quetiapine’, ‘sertindole’, ‘aripiprazole’, ‘paliperidone’, ‘amisulpride’, ‘zotepine’, ‘asenapine’, ‘iloperidone’, ‘lurasidone’, ‘perospirone’ and ‘blonanserin’ in the article titles. Certain bibliometric indicators of production and dispersion (e.g. Price’s Law on the increase of scientific literature, and Bradford’s Law) were applied, and the participation index of various countries was calculated. The bibliometric data was also correlated with some social and health data from Singapore, such as the total per capita expenditure on health and gross domestic expenditure on research and development.
RESULTS From 1997 to 2011, a total of 51 articles on SGAs in Singapore were published. Our results suggested non-fulfilment of Price’s Law (r = 0.0648 after exponential adjustment vs. r = 0.2140 after linear adjustment). The most widely studied drugs were clozapine (21 articles), risperidone (16 articles) and olanzapine (8 articles). Division into Bradford zones yielded a nucleus occupied by the Journal of Clinical Psychopharmacology (6 articles) and the Singapore Medical Journal(4 articles). The analysed material was published in a total of 30 journals, with the majority from six journals. Four of these six journals have an impact factor greater than 2.
CONCLUSION Publications on SGAs in Singapore are still too few to confirm an exponential growth of scientific literature.
Keywords: atypical antipsychotics, bibliometry, schizophrenia, second-generation antipsychotics, Singapore
Singapore Med J 2014; 55(1): 24-33; http://dx.doi.org/10.11622/smedj.2014006
REFERENCES
1. Goldner EM, Hsu L, Waraich P, Somers JM. Prevalence and incidence studies of schizophrenia disorder: a systematic review of literature. Can J Psychiatry 2002; 47:833-43. PMid:12500753 | ||||
2. World Health Organization. Mental Health: New Understanding, New Hope. Geneva: WHO, 2001. | ||||
3. López-Mu-oz F, Alamo C, Cuenca E, et al. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry 2005; 17:113-35. http://dx.doi.org/10.1080/10401230591002002 | ||||
4. Shen WW. A history of antipsychotic drug development. Compr Psychiatry 1999; 40:407-14. http://dx.doi.org/10.1016/S0010-440X(99)90082-2 | ||||
5. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:780-96. http://dx.doi.org/10.1001/archpsyc.1988.01800330013001 | ||||
6. Hippius H. A historical perspective of clozapine. J Clin Psychiatry 1999; 60 (Suppl 12):22-3. PMid:10372606 | ||||
7. López-Mu-oz F, Álamo C. Neurobiological background for the development of new drugs in schizophrenia. Clin Neuropharmacol 2011; 34:111-26. http://dx.doi.org/10.1097/WNF.0b013e318215c2f7 PMid:21586917 | ||||
8. López-Mu-oz F, Vieta E, Rubio G, García-García P, Álamo C. Bipolar disorder as an emerging pathology in the scientific literature: a bibliometric approach. J Affect Disord 2006; 92:161-70. http://dx.doi.org/10.1016/j.jad.2006.02.006 | ||||
9. Chong SA. Mental health in Singapore: a quiet revolution? Ann Acad Med Singapore 2007; 36:795-6. PMid:17987227 | ||||
10. Verma S, Chan LL, Chee KS, et al. Ministry of Health clinical practice guidelines: schizophrenia. Singapore Med J 2011; 52:521-5. PMid:21808964 | ||||
11. Mok YM, Chan HN, Chee KS, et al. Ministry of Health clinical practice guidelines: bipolar disorder. Singapore Med J 2011; 52:914-9. PMid:22159936 | ||||
12. White HD, McCain KW. Bibliometrics. Ann Rev Inf Sci Technol 1989; 24:119-86. | ||||
13. López-Mu-oz F, Álamo C, Rubio G, et al. Bibliometric analysis of biomedical publications on SSRIs during the period 1980-2000. Depress Anxiety 2003; 18:95-103. http://dx.doi.org/10.1002/da.10121 | ||||
14. López-Mu-oz F, Álamo C, Quintero-Gutiérrez FJ, García-García P. A bibliometric study of international scientific productivity in attention-deficit hyperactivity disorder covering the period 1980-2005. Eur Child Adolesc Psychiatry 2008; 17:381-91. http://dx.doi.org/10.1007/s00787-008-0680-1 | ||||
15. López-Mu-oz F, García-García P, Sáiz-Ruiz J, et al. A bibliometric study of the use of the classification and diagnostic systems in psychiatry over the last 25 years. Psychopathology 2008; 41:214-25. http://dx.doi.org/10.1159/000125555 | ||||
16. López-Mu-oz F, Shen WW, Moreno R, et al. International scientific productivity on second-generation antipsychotic drugs in Taiwan: a bibliometric study. Taiwanese J Psychiatry 2012; 26:114-29. | ||||
17. López-Mu-oz F, Shen WW, Pae CU, et al. Trends in scientific literature on atypical antipsychotic drugs in South Korea: A bibliometric study. Psychiatr Invest 2013; 10:8-16. http://dx.doi.org/10.4306/pi.2013.10.1.8 | ||||
18. Price DJS. Little Science, Big Science. New York: Columbia University Press; 1963. | ||||
19. Bradford SC. Documentation. London: Crosby Lockwood; 1948. | ||||
20. Organization for Economic and Co-operational Development Health Division. OECD Health Data 2011: Frequently Requested Data (June 30, 2011). Paris: OECD; 2011. | ||||
21. World Health Organization. WHO Department of Health Statistics and Informatics, 2011: World Health Statistics 2011 (May 13, 2011). Geneva: WHO, 2011. | ||||
22. Johnson MH, Cohen J, Grudzinskas G. The uses and abuses of bibliometrics. Rep BioMed Online 2012; 24:485-6. http://dx.doi.org/10.1016/j.rbmo.2012.03.007 | ||||
23. Nakano W, Yoshimura R, Yang S. The characteristics of pharmacotherapy for inpatients with schizophrenia: a multicentre comparative study in Asia. Eur Neuropsychopharmacol 2010; 20:S467-8. http://dx.doi.org/10.1016/S0924-977X(10)70688-X | ||||
24. Xiang YT, Wang CY, Si TM, et al. Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001-2009). Pharmacopsychiatry 2012; 45:7-12. http://dx.doi.org/10.1055/s-0031-1286345 | ||||
25. Shen WW. Clinical Psychopharmacology for the 21 Century, Third Edition (in Chinese). Taipei: Ho-Chi Publishing Company; 2011. | ||||
26. Fountoulakis KN, Nimatoudis I, Iacovides A, Kaprinis G. Off-label indications for atypical antipsychotics: a systematic review. Ann Gen Hosp Psychiatry 2004; 3:4. http://dx.doi.org/10.1186/1475-2832-3-4 | ||||
27. Mortimer AM, Shepherd CJ, Rymer M, Burrows A. Primary care use of antipsychotic drugs: an audit and intervention study. Ann Gen Psychiatry 2005; 4:18-26. http://dx.doi.org/10.1186/1744-859X-4-18 | ||||
28. Clement S, Singh S, Burns T. Status of bipolar disorder research. Bibliometric study. Br J Psychiatry 2003; 182:148-52. http://dx.doi.org/10.1192/bjp.182.2.148 | ||||
29. Theander SS, Wetterberg L. Schizophrenia in Medline 1950-2006: a bibliometric investigation. Schizophr Res 2010; 118:279-84. http://dx.doi.org/10.1016/j.schres.2009.05.013 | ||||
30. Chong MY, Tan CH, Fujii S, et al. Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry Clin Neurosci 2004; 58:61-7. http://dx.doi.org/10.1111/j.1440-1819.2004.01194.x | ||||
31. Sim K, Su HC, Fujii S, et al. Low doses of antipsychotic drugs for hospitalized schizophrenia patients in East Asia: 2004 vs. 2001. Int J Neuropsychopharmacol 2009; 12:117-23. http://dx.doi.org/10.1017/S1461145708009280 | ||||
32. Tan CH, Shinfuku N, Sim K. Psychotropic prescription practices in East Asia: looking back and peering ahead. Curr Opin Psychiatry 2008; 21:645-50. http://dx.doi.org/10.1097/YCO.0b013e32830e6dc4 | ||||
33. Sim K, Su HC, Fujii S, et al. High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies. Br J Clin Pharmacol 2009; 67:110-7. http://dx.doi.org/10.1111/j.1365-2125.2008.03304.x | ||||
34. Xiang YT, Wang CY, Si TM, et al. Clozapine use in schizophrenia: findings of the Research on Asia Psychotropic Prescription (REAP) studies from 2001 to 2009. Aust N Z J Psychiatry 2011; 45:968-75. http://dx.doi.org/10.3109/00048674.2011.607426 |